Thomas L. Petty Aspen Lung Conference: 62nd Annual Meeting - Exploring New Therapeutic Pathways in PH: Metabolism, Proliferation, and Personalized Medicine

Thomas L. Petty Aspen Lung Conference: 62nd Annual Meeting - Exploring New Therapeutic Pathways in PH: Metabolism, Proliferation, and Personalized Medicine is organized by University of Colorado (CU) Denver and will be held from Jun 05 - 08, 2019 at The Gant, Aspen, Colorado, United States of America.

The target audience for this medical event is Local/Regional/National/International Physicians/Clinicians (adult and pediatric)/Research Physician-Scientists in Pulmonary Sciences, Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine Physicians/Public Health. This CME Conference has been approved for a maximum of 13 AMA PRA Category 1 Credits.

The theme of the conference will be "Exploring New Therapeutic Pathways in Pulmonary Hypertension: Metabolism, Proliferation and Personalized Medicine".

The pulmonary hypertension (PH) field has increasingly recognized that the pulmonary vascular pathology has neoplastic-like features, including the identification of key shared pathophysiology commonalities and has now spawned clinical trials of chemotherapy agents in patients with PH. The 2019 Thomas L. Petty Aspen Lung Conference will explore the common mechanisms found in neoplasia and PH, with the overall goal of translating our understanding of cellular metabolism, proliferation and signaling into more effective therapies for patients with PH.

The four days of the conference will integrate basic, translational, and clinical approaches while focusing on the following themes in PH: Cellular Metabolism, Hypoxia Signaling, Aberrant Cellular Proliferation and Personalized Medicine.

Conference Objectives:
• To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts in the pathogenesis and treatment of PH.
• To stimulate interactions between the fields of pulmonology, cardiology and oncology with the goal of identifying emerging, shared interests that will lead to more efficient and productive research.
• To advance our understanding of clinical and molecular PH pathobiology in order to translate preclinical findings to more effective, personalized therapies.
• To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of PH pathobiology. Finally, the varied scientific themes and therapeutic strategies emerging during the conference will be reconciled in a concluding Conference Summary presented by Mark Gladwin, M.D., Chair of Medicine at the University of Pittsburgh.